In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

forbes.com - 2026-06-17 12:30:08

One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026.

fool.com - 2026-05-31 12:11:48

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will now present at the 2026 Jefferies Global Healthcare Conference at 2:00 p.m. ET on Thursday, June 4, 2026.

globenewswire.com - 2026-05-28 16:01:00

CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the pricing of an underwritten public offering of 55,555,556 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 55,555,556 shares of common stock (or pre-funded warrants in lieu thereof). Each share of common stock and accompanying common stock warrant are being sold together at a combined public offering price of $2.25. The aggregate gross proceeds from the offering are expected to be approximately $125.0 million (assuming no exercise of the common stock warrants), before deducting underwriting discounts and commissions and offering expenses. If all of the common stock warrants are exercised at their exercise price, the Company would receive additional gross proceeds from the offering of approximately $194.4 million before deducting underwriting discounts and commissions and offering expenses.

globenewswire.com - 2026-05-26 09:05:00

CAMBRIDGE, Mass. , May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced that it has commenced an underwritten public offering of its common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) and accompanying warrants to purchase shares of common stock (or pre-funded warrants in lieu thereof).

globenewswire.com - 2026-05-26 06:15:03

CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced that it has commenced an underwritten public offering of its common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) and accompanying warrants to purchase shares of common stock (or pre-funded warrants in lieu thereof). All of the securities in the offering are to be sold by Editas Medicine.

globenewswire.com - 2026-05-26 06:15:00

Single dose of EDIT-401 achieved ~90% or greater mean reductions in LDL-C, Lp(a), and ApoB in non-human primates Data reinforce differentiated LDLR upregulation approach with rapid, dose-dependent effects on multiple atherogenic lipoproteins Company on track to submit CTN by mid-2026 for EDIT-401 and achieve early in vivo human proof-of-concept data by the end of 2026 CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, presented new preclinical data for EDIT-401, its lead in vivo development candidate, in an oral presentation at the 94th European Atherosclerosis Society (EAS) Congress in Athens, Greece on May 25, 2026.

globenewswire.com - 2026-05-26 06:01:00

CAMBRIDGE, Mass. , May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical data supporting the continued advancement of Editas' lead in vivo development candidate, EDIT-401, and its potential as a one-time treatment for hyperlipidemia, as well as the broader potential of the Company's differentiated upregulation strategy.

globenewswire.com - 2026-05-14 06:01:00

New data demonstrate promising preclinical safety profile and durable LDL-C lowering of ≥90% with single dose of EDIT-401 in non-human primates through ~6 months New data demonstrate promising preclinical safety profile and durable LDL-C lowering of ≥90% with single dose of EDIT-401 in non-human primates through ~6 months

globenewswire.com - 2026-05-14 06:01:00

Editas narrows Q1 loss as costs fall, but revenues drop sharply. Pipeline focus shifts to in vivo gene editing and lead candidate EDIT-401.

zacks.com - 2026-05-06 13:01:32

Editas Medicine (EDIT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.43 per share a year ago.

zacks.com - 2026-05-05 09:26:26

EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, on track to achieve early human proof-of-concept data by year-end 2026  Company to present new EDIT-401 preclinical data at upcoming scientific meetings, including data showing significant reductions in Lp(a) and ApoB in non-human primates at the 94th EAS Congress U.S. Patent and Trademark Office reaffirmed prior decision in favor of the Broad Institute in CRISPR/Cas9 interference CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the first quarter 2026 and provided business updates.

globenewswire.com - 2026-05-05 07:00:00

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that five abstracts have been accepted for presentation, including one oral presentation and two poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, one oral presentation at TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference, and one oral presentation at the 94th European Atherosclerosis Society (EAS) Congress. The Company is presenting new preclinical data, including data to support the potential of EDIT-401, its lead in vivo development candidate, to be a transformative therapy for people living with hyperlipidemia.

globenewswire.com - 2026-04-27 16:31:00